Crucell Appoints Agents to Boost Asian Market Potential

21-Sep-2005

Crucell N.V. announced that it has entered into agreements with Pharma&Soft in South Korea and Biott in Japan to increase the licensing business for PER.C6® and Advac® technology in Asia.

Under the contracts, the two agencies shall help Crucell to contact and secure agreements with prospective Korean and Japanese PER.C6® and Advac® licensees for the development and manufacturing of vaccines and gene therapy. They will also offer further support where useful.

Other news from the department business & finance

Most read news

More news from our other portals

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world
Topic world Gene therapy

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.